Tobeka Naki

400 citations
12 papers · 288 indexed · h-index 6
Topics
Nanoparticle-Based Drug Delivery (6 papers)RNA Interference and Gene Delivery (5 papers)Advanced Drug Delivery Systems (4 papers)
Partner nations
South Africa

In The Last Decade

Tobeka Naki

8 papers receiving 284 citations

Peers

Tobeka Naki
Comparison fields: 5 of 64
  • Organic Chemistry 105
  • Molecular Biology 84
  • Pharmaceutical Science 74
  • Biomaterials 66
  • Public Health, Environmental and Occupational Health 30
Replace Shaimaa K. Mostafa with:
Shaimaa K. Mostafa Egypt
Sumit Birangal India
Prasanna Raju Yalavarthi India
Rahul Sonawane India
Shirin Mollazadeh Iran
Kayla M. Pate United States
Mariana Matias Portugal
Anita Sztojkov‐Ivanov Hungary
Chinazom Precious Agbo Nigeria
Sugin Lal Jabaris S India
Tobeka Naki relative to Shaimaa K. Mostafa Egypt Shaimaa K. Mostafa's profile →
Citations per field
00.5×4.8×
Shaimaa K. Mostafa · 1×
Citations per year

Countries citing papers authored by Tobeka Naki

Since Specialization
Citations

This map shows the geographic impact of Tobeka Naki's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tobeka Naki with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tobeka Naki more than expected).

Fields of papers citing papers by Tobeka Naki

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tobeka Naki. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tobeka Naki. The network helps show where Tobeka Naki may publish in the future.

Co-authorship network of co-authors of Tobeka Naki

This figure shows the co-authorship network connecting the top 25 collaborators of Tobeka Naki. A scholar is included among the top collaborators of Tobeka Naki based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tobeka Naki. Tobeka Naki is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

12 of 12 papers shown
#WorkIndexed citations
1 2
2 0
3 0
4 0
5 8
6 24
7 0
8 7
9 4
10 72
11 47
12 124

About Tobeka Naki

Tobeka Naki is a scholar working on Pharmaceutical Science, Biomaterials and Neurology, having authored 12 papers that have together received 288 indexed citations. Recurring topics across this work include Nanoparticle-Based Drug Delivery (6 papers), RNA Interference and Gene Delivery (5 papers) and Advanced Drug Delivery Systems (4 papers). The work is most often cited by research in Pharmaceutical Science (74 citations), Biomaterials (66 citations) and Organic Chemistry (105 citations). Tobeka Naki has collaborated with scholars based in South Africa. Frequent co-authors include Blessing A. Aderibigbe, Xhamla Nqoro, Buhle Buyana, Sibusiso Alven, Mohammed O. Balogun, Suprakas Sinha Ray, Vanessa Steenkamp, Samuel Egieyeh, Nicholas Rono and Philemon Ubanako. Their work appears in journals such as International Journal of Molecular Sciences, Molecules and Applied Sciences.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026